7.50 Check-In & Morning Coffee
8:50 am Chair’s Opening Remarks
Unlocking the Future Outlook of RNA & Beyond: The Leadership Perspective Within a Thriving Asian Ecosystem
9:00 am Unlocking Recent Clinical Progress of mRNA-Based Vaccines & B-Cell Depletion Therapies
Synopsis
- Demonstrating Abogen’s unique mRNA and LNP platform
- Sharing clinical data and progress of mRNA cancer vaccines
- Accelerating preclinical and clinical development of mRNA-based T-cell engagers and in vivo CAR-T
9:30 am Advancing mRNA-Based In Vivo CAR-T Cell Therapy
Synopsis
- Innovation: Engineering antibody-conjugated LNP deliver mRNA to reprogram immune cells in vivo, bypassing ex vivo manufacturing
- Advantage: Enabling transient, controlled CAR expression with reduced off target toxicity
- Proof of concept: Showcasing pre-clinical efficacy and safety with preliminary human trials results
10:00 am CEO Leaders Think Tank – Accelerating the Next Wave of RNA-Based Therapeutics & Vaccines to Develop Safe & Efficacious Drugs to Commercial Reality
Synopsis
The Asian biopharmaceutical sector is thriving in RNA innovation, manufacturing advancements and strategic alliances to enhance the knowledge, skills, and experience across the region to become the powerhouse of commercial success. Hear from pioneering executive leaders across mRNA and next generation RNAs who will discuss their ambitions, strategies and challenges for the future of this technology, the hottest indications of unmet need and progress towards the next commercial approval.
- What are the future opportunities, promising targets and applications on the horizon for RNA therapeutics, vaccines and gene editing tools to achieve clinical success?
- How to develop and de-risk RNA platforms in the competitive Asian and Pacific markets
- What are the biggest challenges to overcome when it comes to science vs strategy and pipeline management for 2025/26?
10:30 am Morning Break & Speed Networking
Synopsis
This networking session is your opportunity to get face-to-face with many of the brightest minds working in the RNA field and establish meaningful scientific collaboration and business relationships to pursue for the rest of the conference.
Accelerating RNA Production & Processes with Innovation to Achieve Efficiency & Cost- Effectiveness at Scale
11:30 am PureCap: Demonstrating an Ultra-Pure Next-Generation mRNA Cap Analog with Significantly Improved Potency Profile
Synopsis
- The development of high quality mRNA vaccines and therapeutics hinges on the optimization of mRNA synthesis, particularly the capping process. PureCap is a nextgeneration mRNA cap analog designed to address key challenges in the field: purity, potency, and scalability
- Utilizing a photo-labile cap to deliver an ultra pure fully capped, fully functional mRNA product with significantly reduced levels of double stranded RNA and minimizing unwanted immune activation and enhancing safety profiles
- Illustrating PureCap as a promising solution for enhancing the performance of mRNAbased therapies and vaccines, improving both efficacy and safety at an industrial scale
12:00 pm A Comprehensive Journey Towards High-Quality GMP IVT Enzymes & Raw Materials with Enhanced Scale-Up Robustness and GMP-Ready Filtration
Synopsis
- Presenting an mRNA market overview
- The quest for high-quality GMP raw materials and the journey of bringing the products to market
- The development of GMP-ready filtration and application of RAMAN technology for Improved efficiency
12:30 pm Development of Alternative Analytical Method for mRNA Product Characterization
Synopsis
- Highlighting innovative approaches for mRNA LNP encapsulation efficiency assessment
- Showcasing the development of an innovative RNase protection assay for EE measurement
- Identifying future challenges in RNA-LNP characterization
1:00 pm Lunch Break
2:00 pm Th-Vac® Platform: AI-Based in Silico Epitope Screening for CD4+ T Cell- Mediated mRNA Cancer Vaccine Immunotherapy
Synopsis
- Th-Vac® is an AI-powered system designed to help create mRNA cancer vaccines that activate CD4+ helper T cells
- Harnessing this technology to develop mRNA vaccines that can specifically target cancer associated antigens such as TROP2, PD-L1, IDO, and KRAS
- Addressing the current challenges in cancer immunotherapy and enhancing future treatment options
3:00 pm WGc-0201: A Breakthrough mRNA Immunotherapy for HBV-Associated Liver Cancer
Synopsis
- Addressing a critical unmet need in Asia by targeting HBV-driven hepatocellular carcinoma with a novel mRNA-based cancer vaccine
- Demonstrating early clinical signals of durable disease control and strong immunogenicity in heavily pretreated patients
- Developing these therapies using WestGene's proprietary LNP and Immuno-Enhancer (IE) platforms, achieving enhanced safety and immune activation for optimal therapeutic impact
3:30 pm Afternoon Break & Scientific Poster Session
Synopsis
As the landscape of innovation in Asia is enabling scalable, cost-effective and commercially viable
RNA therapeutics and vaccines, it is more important than ever to collaborate and learn for the growth
of this field. Join our dedicated poster session to share your latest data and have a first look into what
your peers are working on.
Unleashing Novel LNP Formulations & Beyond to Exploit the Full Potential of Non-Viral Delivery Vehicles by Ensuring Safe & Targeted RNA Therapeutic Delivery
4:00 pm Emerging Ionizable Lipids: Innovation & Applications in Therapies & Vaccines
Synopsis
- Developing novel ionizable lipids for gene and cell therapy
- Formulating immune modulating ionizable lipids
- Achieving targeted delivery of mRNA/LNP beyond liver
4:30 pm Polypeptide Lipid-Engineered PEG-Free LNPs for Targeted Delivery of mRNA Vaccines
Synopsis
- Harnessing PEG-free LNPs deliver mRNA vaccine to lymph nodes with minimal accumulation in the liver
- Achieving no anti-polypeptide lipid antibody response after repeated dosing
- Eliciting stronger and more durable immune response with PEG-free LNPs than PEGylated ALC LNPs
5:00 pm Designing LNPs with Proprietary Ionizable Lipids to Expand the Possibilities for mRNA Delivery
Synopsis
- LNPs for enhanced mRNA delivery efficiency in NHPs
- Controlling tissue tropism by designing LNPs
- End-to-end CDMO services for mRNA-LNP
5:10 pm Targeting Beyond the Liver – Achieving Organ-Specific Delivery with Next- Generation Lipid Libraries, Formulations & Payload Optimizations
Synopsis
- How can we improve lipid nanoparticle design for organ-specific delivery to expand the therapeutic range of LNPs?
- Unleashing AI-assisted and machine learning capabilities to screen novel lipids with distinct organ tropism, enhancing efficacy while reducing toxicity to broaden the dosing window
- Assessing current LNP engineering strategies and library designs for optimal screening and effective extra-hepatic targeting